LoadingLoadingLoading39 funds hold it.Insiders net selling.
Net selling: insiders sold $18M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $30K to $100K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Financial period
Third-Quarter 2026
Earnings per share
$2.08 expected
Revenue
$17.35B expected
Full Year 2026 guidance
$66.80B to $67.30B
No comparable estimate
Estimates as of Nov 4, 2026
EPS expected
$1.71 to $2.10
Revenue expected
15 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $2.49est. $2.08 | +19.59%beat | $18.09Best. $17.35B+4.25% | +4.7%from $17.28B |
| Jun 30, 2026Reported Aug 4, 2026 | -$0.13est. -$0.26 | +49.43%beat | $16.61BSEC filing | +5.1%from $15.81B |
| Mar 31, 2026Reported Apr 30, 2026 | -$1.28est. -$1.47 | +13.15%beat | $16.29BSEC filing | +4.9%from $15.53B |
| Dec 31, 2025Reported Feb 3, 2026 | $2.04est. $2.01 | +1.47%beat | $16.32BAlpha Vantage | +4.5%from $15.62B |
| Sep 30, 2025Reported Oct 30, 2025 | $2.58est. $2.35 | +9.79%beat | $17.28BSEC filing | +3.7%from $16.66B |
| Jun 30, 2025Reported Jul 29, 2025 | $2.13est. $2.03 | +4.93%beat | $15.81BSEC filing | -1.9%from $16.11B |
| Mar 31, 2025Reported Apr 24, 2025 | $2.22est. $2.14 | +3.74%beat | $15.53BSEC filing | -1.6%from $15.78B |
| Dec 31, 2024Reported Feb 4, 2025 | $1.72est. $1.67 | +2.99%beat | $15.62BAlpha Vantage | +6.8%from $14.63B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $16.32B | $16.29B | $16.61B | $18.09B |
| Cost of what it sold | $4.82B | $2.94B | $4.39B | $3.36B |
| Gross profit | $11.51B | $13.34B | $12.21B | $14.73B |
| What it spent | ||||
| Research and development | $2.50B | $12.56B | $9.74B | $4.53B |
| Sales and admin | $2.85B | $2.70B | $2.90B | $2.89B |
| Other operating costs | — | — | $250.0M | — |
| Total operating expenses | $5.35B | $15.23B | $12.89B | $7.39B |
| What was left | ||||
| Operating profit | $6.16B | -$1.88B | -$683.0M | $7.33B |
| Interest on debt | $411.0M | $479.0M | $525.0M | $546.0M |
| Profit before tax | $3.42B | -$3.53B | -$683.0M | $5.56B |
| Tax | $458.0M | $709.0M | $654.0M | $492.0M |
| Net profit | $2.96B | -$4.24B | -$1.33B | $5.07B |
| EBITDA | $6.30B | -$2.02B | $1.43B | $7.33B |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Tandem Diabetes Taps GE HealthCare Exec Jeannette Bankes as CEO
NeutralNov 6The One Thing To Settle Before Buying AbbVie Stock
NeutralNov 6Recombinant DNA Technology Market: Industry Developments
BullishNov 6Citius Oncology Presents LYMPHIR Quality-of-Life Data at EORTC Meeting
NeutralNov 6Cigna Lifts 2026 Profit Target to $30.60 a Share as Specialty Pharmacy Delivers
NeutralNov 6Elanco Animal Health Reports Soon: How Has The Stock Reacted To Past Earnings?
NeutralNov 6Johnson & Johnson wins FDA approval for Rybrevant cancer treatment
NeutralNov 6Halozyme Q3 2026: Record Royalties Drive a Guidance Raise
BearishNov 6
